These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 29566741)

  • 1. The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours.
    El Ansari R; Craze ML; Miligy I; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res; 2018 Mar; 20(1):21. PubMed ID: 29566741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer.
    El-Ansari R; Craze ML; Alfarsi L; Soria D; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res Treat; 2019 May; 175(1):27-38. PubMed ID: 30671766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes.
    El Ansari R; Craze ML; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
    Br J Cancer; 2018 Apr; 118(8):1115-1122. PubMed ID: 29545595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer.
    El Ansari R; Alfarsi L; Craze ML; Masisi BK; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res Treat; 2020 May; 181(1):1-12. PubMed ID: 32200487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours.
    Green AR; Aleskandarany MA; Agarwal D; Elsheikh S; Nolan CC; Diez-Rodriguez M; Macmillan RD; Ball GR; Caldas C; Madhusudan S; Ellis IO; Rakha EA
    Br J Cancer; 2016 Apr; 114(8):917-28. PubMed ID: 26954716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer.
    Alfarsi LH; El-Ansari R; Craze ML; Masisi BK; Mohammed OJ; Ellis IO; Rakha EA; Green AR
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SLC7A5 is linked to increased expression of genes related to proliferation and hypoxia in estrogen‑receptor‑positive breast cancer.
    Törnroos R; Tina E; Göthlin Eremo A
    Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34792178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis.
    Aleskandarany MA; Abduljabbar R; Ashankyty I; Elmouna A; Jerjees D; Ali S; Buluwela L; Diez-Rodriguez M; Caldas C; Green AR; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2016 Sep; 159(2):215-27. PubMed ID: 27514395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The amino acid transporter SLC7A11 expression in breast cancer.
    Nath P; Alfarsi LH; El-Ansari R; Masisi BK; Erkan B; Fakroun A; Ellis IO; Rakha EA; Green AR
    Cancer Biol Ther; 2024 Dec; 25(1):2291855. PubMed ID: 38073087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer.
    Joseph C; Arshad M; Kurozomi S; Althobiti M; Miligy IM; Al-Izzi S; Toss MS; Goh FQ; Johnston SJ; Martin SG; Ellis IO; Mongan NP; Green AR; Rakha EA
    Breast Cancer Res Treat; 2019 Apr; 174(2):387-399. PubMed ID: 30554343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYC amplification in subtypes of breast cancers in African American women.
    Naab TJ; Gautam A; Ricks-Santi L; Esnakula AK; Kanaan YM; DeWitty RL; Asgedom G; Makambi KH; Abawi M; Blancato JK
    BMC Cancer; 2018 Mar; 18(1):274. PubMed ID: 29523126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer.
    Craze ML; Cheung H; Jewa N; Coimbra NDM; Soria D; El-Ansari R; Aleskandarany MA; Wai Cheng K; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
    Br J Cancer; 2018 Jan; 118(2):258-265. PubMed ID: 29169183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes.
    Joseph C; Macnamara O; Craze M; Russell R; Provenzano E; Nolan CC; Diez-Rodriguez M; Sonbul SN; Aleskandarany MA; Green AR; Rakha EA; Ellis IO; Mukherjee A
    Br J Cancer; 2018 Apr; 118(8):1142-1151. PubMed ID: 29588513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer.
    Aljohani AI; Joseph C; Kurozumi S; Mohammed OJ; Miligy IM; Green AR; Rakha EA
    Breast Cancer Res Treat; 2020 Jun; 181(3):541-551. PubMed ID: 32350677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes.
    Althobiti M; Muftah AA; Aleskandarany MA; Joseph C; Toss MS; Green A; Rakha E
    Breast Cancer Res Treat; 2020 Aug; 182(3):581-589. PubMed ID: 32524353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy.
    Alfarsi LH; Ansari RE; Craze ML; Toss MS; Masisi B; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res Treat; 2019 Dec; 178(3):535-544. PubMed ID: 31471836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The oestrogen receptor coactivator CARM1 has an oncogenic effect and is associated with poor prognosis in breast cancer.
    Habashy HO; Rakha EA; Ellis IO; Powe DG
    Breast Cancer Res Treat; 2013 Jul; 140(2):307-16. PubMed ID: 23887673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD133 expression is associated with less DNA repair, better response to chemotherapy and survival in ER-positive/HER2-negative breast cancer.
    Sato T; Oshi M; Huang JL; Chida K; Roy AM; Endo I; Takabe K
    Breast Cancer Res Treat; 2024 Nov; 208(2):415-427. PubMed ID: 39017815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer.
    Althobiti M; El-Sharawy KA; Joseph C; Aleskandarany M; Toss MS; Green AR; Rakha EA
    Breast Cancer Res Treat; 2021 Oct; 189(3):621-630. PubMed ID: 34453638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glutamate dehydrogenase (GLUD1) expression in breast cancer.
    Craze ML; El-Ansari R; Aleskandarany MA; Cheng KW; Alfarsi L; Masisi B; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res Treat; 2019 Feb; 174(1):79-91. PubMed ID: 30470977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.